These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27019798)

  • 1. Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.
    Bugaj AM
    World J Methodol; 2016 Mar; 6(1):65-76. PubMed ID: 27019798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.
    Nogueira L; Tracey AT; Alvim R; Reisz P; Scherz A; Coleman JA; Kim K
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33228126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
    Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
    Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
    Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
    Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
    Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
    Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
    Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
    Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
    Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M;
    Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy for prostate cancer - A narrative review.
    Osuchowski M; Bartusik-Aebisher D; Osuchowski F; Aebisher D
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102158. PubMed ID: 33352313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
    Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
    Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
    Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
    Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
    Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
    [No Abstract]   [Full Text] [Related]  

  • 17. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
    Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
    Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
    [No Abstract]   [Full Text] [Related]  

  • 19. Follow-up of vascular-targeted photodynamic therapy in a real-world setting.
    Borkowetz A; Kwe J; Boehm K; Baunacke M; Herout R; Lucke M; Burcea A; Thomas C
    World J Urol; 2024 Jan; 42(1):55. PubMed ID: 38244089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
    Lebdai S; Bigot P; Leroux PA; Berthelot LP; Maulaz P; Azzouzi AR
    J Urol; 2017 Aug; 198(2):335-344. PubMed ID: 28322857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.